Tirzepatide is the first approved twincretin — and it beat the field's prior champion head-to-head in two separate trials.

The short version

Tirzepatide is a once-weekly injection approved by the FDA for type 2 diabetes (2022), obesity (2023), and obstructive sleep apnea (2024). It is the first drug to work on two gut hormone signals at the same time — GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1). Both of these are natural signals your gut sends after a meal to tell your pancreas to release insulin. By hitting both signals with a single molecule, tirzepatide produces larger reductions in blood sugar and body weight than older drugs that only hit GLP-1 alone. In the biggest obesity trial to date (SURMOUNT-1, 2,539 people), participants at the highest dose lost an average of 20.9% of their body weight over 72 weeks ^[4]. In a head-to-head comparison against semaglutide in people without diabetes (SURMOUNT-5), tirzepatide produced -20.2% weight loss versus -13.7% ^[5]. The most common side effects are nausea, constipation, and diarrhea — mostly during dose escalation. What people report — including the downsides — is covered on the effects page.

Tirzepatide: what the trial record actually shows

Tirzepatide is a 39-amino-acid synthetic peptide engineered on the GIP backbone, modified with a C20 fatty-diacid arm that confers high albumin affinity and a ~5-day elimination half-life — the property that makes once-weekly dosing viable ^[1].

The molecule's defining feature is dual agonism. It activates both the GIP receptor and the GLP-1 receptor, but it does not hit them equally: in vitro work established it engages the GIP receptor more fully than the GLP-1 receptor — an 'imbalanced' dual agonist — and its GLP-1 receptor signalling is biased toward cAMP generation over beta-arrestin recruitment, a property that may enhance insulin secretion ^[2].

The SURPASS trial programme tested Tirzepatide in type 2 diabetes across five large randomised trials. SURPASS-1 (monotherapy vs placebo) showed dose-dependent HbA1c and weight reduction ^[8]. SURPASS-2 (vs semaglutide 1 mg, n=1,879, 40 weeks) produced HbA1c reductions of -2.01, -2.24, and -2.30 percentage points at 5, 10, and 15 mg respectively, versus -1.86 points with semaglutide — tirzepatide was noninferior and superior at all three doses ^[3]. Body weight differences were -1.9, -3.6, and -5.5 kg in favour of tirzepatide ^[3]. Tirzepatide research covers the full SURPASS and SURMOUNT record.

The SURMOUNT programme tested Tirzepatide in obesity. SURMOUNT-1 (n=2,539, 72 weeks, non-diabetic participants) found mean weight changes of -15.0%, -19.5%, and -20.9% at 5, 10, and 15 mg versus -3.1% with placebo ^[4]. SURMOUNT-5, a head-to-head against semaglutide in 751 non-diabetic adults, found -20.2% with tirzepatide versus -13.7% with semaglutide — tirzepatide superior across all weight-loss thresholds ^[5].

Beyond glycaemia and obesity, readouts have followed: SUMMIT (heart failure with preserved ejection fraction), SURMOUNT-OSA (obstructive sleep apnea), and SYNERGY-NASH (metabolic dysfunction-associated steatohepatitis, a form of fatty liver disease).

Tirzepatide vs semaglutide

Two separate head-to-head trials have now compared tirzepatide injection with semaglutide directly.

SURPASS-2 (type 2 diabetes, n=1,879, 40 weeks): tirzepatide 5/10/15 mg versus semaglutide 1 mg. HbA1c reduction -2.01/-2.24/-2.30 vs -1.86 percentage points. Weight change treatment differences -1.9/-3.6/-5.5 kg in favour of tirzepatide at each dose. Tirzepatide was noninferior and superior at all three doses tested ^[3].

SURMOUNT-5 (obesity without type 2 diabetes, n=751, 72 weeks): maximum tolerated dose of tirzepatide (10 or 15 mg) versus maximum tolerated dose of semaglutide (1.7 or 2.4 mg). Least-squares mean weight change: -20.2% vs -13.7% (P<0.001). Tirzepatide also produced greater reductions in waist circumference and higher proportions reaching ≥10/15/20/25% weight loss thresholds ^[5].

Note: the comparison in SURPASS-2 was against the 1 mg dose of semaglutide, not the higher obesity doses. SURMOUNT-5 used maximum tolerated doses of both agents.

Tirzepatide weight loss

The SURMOUNT-1 weight-loss finding is the largest yet recorded in a placebo-controlled obesity trial. At 15 mg, 63% of participants lost ≥20% of their body weight over 72 weeks, compared with 1.3% on placebo ^[4]. The trial enrolled adults with obesity (BMI ≥30) or overweight (BMI ≥27 with a weight-related complication) and without type 2 diabetes.

In SURMOUNT-5, the head-to-head against semaglutide, tirzepatide produced -20.2% weight loss versus -13.7% ^[5]. Both trials used a 20-week escalation schedule before reaching maintenance doses.

Tirzepatide results in SURPASS-2 also included weight loss as a secondary endpoint, with treatment differences of up to -5.5 kg at the highest dose versus semaglutide 1 mg ^[3].

A SURMOUNT-1 body composition substudy found that approximately 25% of weight lost was lean mass, with the remaining ~75% fat mass ^[12]. The clinical significance of this lean-mass loss is under active investigation.

Tirzepatide reviews

Across the SURPASS and SURMOUNT programmes, tirzepatide produced the most consistent and largest glycaemic and weight outcomes of any dual incretin agent tested to date ^[7]. The StatPearls clinical reference confirms it as an FDA-approved dual GLP-1/GIP receptor agonist and summarises the trial record ^[7].

In structured patient interview studies, 79-91% of SURMOUNT trial participants described reduced appetite as a top benefit, and roughly 62-79% reported increased energy over the treatment course. Approximately 47-55% described improved mood and self-confidence. These are patient-reported experiences, not controlled trial endpoints — see Tirzepatide effects for the full community-signal picture.

Tirzepatide results in randomised trials are replicated across multiple independent comparisons — SURPASS-1 through -5 and SURMOUNT-1 and -5 — with consistent dose-response patterns at 5, 10, and 15 mg.

Tirzepatide peptide

Tirzepatide is a synthetic 39-amino-acid peptide built on the native GIP sequence. Its molecular formula is C225H348N48O68, molecular weight 4813.53 Da, CAS number 2023788-19-2, ATC code A10BX16. The fatty-diacid modification — a C20 eicosanedioic acid attached via a glutamic acid linker and two aminoethoxyethoxyacetic acid units to a lysine side chain — confers high albumin affinity, yielding the ~5-day elimination half-life that supports once-weekly subcutaneous administration ^[1].

The 'incretin effect' it amplifies describes the phenomenon by which gut hormones (GIP and GLP-1) released after eating enhance insulin secretion from the pancreas in a glucose-dependent manner — meaning the effect is strongest when blood glucose is high and diminishes as it normalises, which is why tirzepatide carries a low intrinsic hypoglycaemia risk on its own ^[7].

The tirzepatide injection page covers subcutaneous administration and the dose-escalation schedule documented in the label and clinical trials.

Tirzepatide cost

Tirzepatide is a prescription medication dispensed through licensed pharmacies and healthcare systems. List pricing for branded formulations is set by the manufacturer and subject to change; actual patient cost depends on insurance coverage, formulary tier, manufacturer assistance programmes, and geography. This site covers the research record — pricing, sourcing, and access are outside the scope of the published efficacy and safety literature. This site does not sell tirzepatide and does not link to any vendor, pharmacy, or compounding source.